

Elan Pharmaceuticals
Application No.: 09/155,739
Page 2

PATENT

IN THE CLAIMS:

Please amend claims 1-26 as follows (Applicants have attached the claims with markings to show changes made as an appendix):

- Sub
C2
1. A method of using a humanized antibody to alpha-4 integrin in the manufacture of a medicament for treating a disease selected from the group consisting of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated lung injury.
 2. The method according to claim 1, wherein the disease is asthma.
 3. The method according to claim 1, wherein the disease is atherosclerosis.
 4. The method according to claim 1, wherein the disease is AIDS dementia.
 5. The method according to claim 1, wherein the disease is diabetes.
 6. The method according to claim 1, wherein the disease is inflammatory bowel disease.
 7. The method according to claim 1, wherein the disease is rheumatoid arthritis.
 8. The method according to claim 1, wherein the disease is transplant rejection.
 9. The method according to claim 1, wherein the disease is graft versus host disease.
 10. The method according to claim 1, wherein the disease is tumor metastasis.
 11. The method according to claim 1, wherein the disease is nephritis.
 12. The method according to claim 1, wherein the disease is atopic dermatitis.
- B2

Elan Pharmaceuticals
Application No.: 09/155,739
Page 3

PATENT

13. The method according to claim 1, wherein the disease is psoriasis.
14. The method according to claim 1, wherein the disease is myocardial ischemia.
15. The method according to claim 1, wherein the disease is acute leukocyte-mediated lung injury.
16. The method according to claim 1, wherein the disease is adult respiratory distress syndrome.
17. The method according to claim 1, wherein the humanized antibody is a humanized form of the mouse 21.6 antibody.
18. The method according to claim 17, wherein the humanized antibody comprises a humanized heavy chain and a humanized light chain:
- (1) the humanized light chain comprising three complementarity determining regions (CDR1, CDR2 and CDR3) having amino acid sequences from the corresponding complementarity determining regions of the mouse 21-6 immunoglobulin light chain variable domain designated SEQ ID No:2, and a variable region framework from a human kappa light chain variable region framework sequence except in at least one position selected from a first group consisting of L45, L49, L58 and L69, wherein the amino acid position is occupied by the same amino acid present in the equivalent position of the mouse 21-6 immunoglobulin light chain variable region framework; and
- (2) the humanized heavy chain comprising three complementarity determining regions (CDR1, CDR2 and CDR3) having amino acid sequences from the corresponding complementarity determining regions of the mouse 21-6 immunoglobulin heavy chain variable domain designated SEQ ID No:4, and a variable region framework from a human heavy chain variable region framework sequence except in at least one position selected from a second group consisting of H27, H28, H29, H30, H44, H71, wherein the amino acid position is occupied by the same amino acid present in the equivalent position of the mouse 21-6 immunoglobulin heavy chain variable region framework;

B2

Sub
CB

Elan Pharmaceuticals
Application N. : 09/155,739
Page 4

PATENT

wherein the humanized immunoglobulin specifically binds to alpha-4 integrin with a binding affinity having a lower limit of about $10^7 M^{-1}$ and an upper limit of about five-times the binding affinity of the mouse 21-6 immunoglobulin.

Sub C3
19. The method according to claim 18, wherein the humanized light chain variable region framework is from an RE1 variable region framework sequence except in at least one position selected from the first group, and except in at least one position selected from a third group consisting of positions L104, L105 and L107, wherein the amino acid position is occupied by the same amino acid present in the equivalent position of a kappa light chain from a human immunoglobulin other than RE1.

20. The method according to claim 19, wherein the humanized heavy chain variable region framework is from a 21/28'CL variable region framework sequence.

B2
21. The method according to claim 20, wherein the humanized light chain variable region framework comprises at least three amino acids from the mouse 21.6 immunoglobulin at positions in the first group and three amino acids from the kappa light chain from the human immunoglobulin other than RE1 at positions in the third group, and the humanized heavy chain variable region framework comprises at least five amino acids from the mouse 21.6 immunoglobulin at positions in the second group.

22. The method according to claim 21, wherein the humanized light chain variable region framework is identical to the RE1 light chain variable region framework sequence except for the at least three positions from the first group and the three positions from the third group, and the heavy chain variable region framework is identical to the 21/28'CL heavy chain variable region framework sequence except for the at least five positions from the second group.

23. The method according to claim 22, wherein at least three positions from the first group are positions L45, L58 and L69, and the at least five positions from the second group are positions H27, H28, H29, H30 and H71.

24. The method according to claim 23, wherein the humanized light chain comprises complementarity determining regions that are identical to the corresponding complementarity determining regions of the mouse 21-6 heavy chain, and